Drugs in Dev. Psychiatry/Psychology
Phase IV
Lead Product(s) : Cytisine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Redwood Scientific Technologies Inc
Deal Size : Undisclosed
Deal Type : Agreement
Redwood Scientific Partners with Jeeva to Study TBX-Free Oral Strips for Cessation
Details : The study aims to test TBX-Free oral strips (cytisine), which stimulate brain receptors similarly to nicotine, for smoking cessation.
Product Name : TBX-FREE
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 02, 2024
Lead Product(s) : Cytisine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Redwood Scientific Technologies Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vyleesi (bremelanotide) is the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD).
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka And Lundbeck Generate Exploratory Data In Major Depressive Disorder Based On Patient Feedback
Details : One of co-primary endpoints of study on adjunctive Rexulti (brexpiprazole) in adults with MDD and inadequate response to ADT was new exploratory outcome focusing on positive health aspects across emotional, physical, social, and cognitive domains.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2022
Lead Product(s) : Brexpiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
